45 -7 (81) 2025 - Badridinov A.S., Khamdamov B.Z. - IMMUNO - METABOLIC CORRELATIONS IN DELAYED CONSOLIDATION OF LONG BONE FRACTURES IN THE POST-COVID PERIOD

IMMUNO - METABOLIC CORRELATIONS IN DELAYED CONSOLIDATION OF LONG BONE FRACTURES IN THE POST-COVID PERIOD

Badridinov A.S. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Khamdamov B.Z. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Asqarov T.A. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The study investigates the correlation between lipid and carbohydrate metabolism indicators and immune-inflammatory markers in patients with delayed consolidation of long bone fractures after COVID-19. A total of 126 patients were analyzed using clinical, biochemical, and immunological parameters. Elevated total cholesterol and LDL were positively associated with increased levels of IgA, IgG, IgE, and pro-inflammatory cytokines (IL-1β, IL-6), and negatively correlated with the osteogenic marker lactoferrin. Hyperglycemia and insulin resistance showed strong positive correlations with humoral immunity markers and systemic inflammation (CRP, IL-6), while inversely correlating with INF-γ, reflecting immune dysregulation. HDL demonstrated a protective role by showing inverse relationships with inflammatory markers. These findings emphasize the pathophysiological significance of immune-metabolic interactions in post-COVID bone healing impairments

Keywords: delayed bone consolidation, lipid profile, carbohydrate metabolism, immunological markers, inflammation, COVID-19, cytokines, lactoferrin, HOMA-IR, immune dysregulation

First page

231

Last page

235

For citation:Badridinov A.S., Khamdamov B.Z., Asqarov T.A. - IMMUNO - METABOLIC CORRELATIONS IN DELAYED CONSOLIDATION OF LONG BONE FRACTURES IN THE POST-COVID PERIOD//New Day in Medicine 7(81)2025 231-235 https://newdayworldmedicine.com/en/new_day_medicine/7-81-2025

List of References

1. Ackermann M,Verleden SE, Kuehnel M et al. Pulmonary vascular endotheliales, thrombosis, and Angiogenesis in covid-19 // N Engl J Med. 2023. V. 383. P. 120-128.
2. Becker, RC COVID 19 update:Covid 19 associated coagulopathy // J Thromb Thrombolysis. 2020. Vol. 50. P. 54–67.
3. Catherine J Wang, ScottWorswick. Cutaneous manifestations of COVID-19 // Dermatol Online J. 2021. T. 27, No. 1. P. 13030/qt2m54r7nv.
4. Dawson P.,Rabold EM, Laws RL, Conners EE, Gharpure R, Yin S, Buono SA, Dasu T, Bhattacharyya S, Westergaard RP, et al. Loss of Taste and Smell as Distinguishing Symptoms of COVID-19 // Clin. Infect. Dis. 2020. T. 21.
5. Fayzullaeva N.Ya., Raufov A.A., Ruzbakieva M.R., Kayumov A.A., Mukhtorov Sh.M. Frequency of polymorphism of the CYP3A5 gene in patients with bronchial asthma, COPD and crossing bronchial asthma and COPD // Journal of theoretical and clinical medicine. 2024 г. P.35-39
6. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study // Travel Med Infect Dis. 2020. T. 34. P. 101663.
7. Hellman, U. Presence ofhyaluronan in lung alveoli in severe Covid-19: An opening for new treatment options? / U. Hellman, M. G. Karlsson, A. Engström-Laurent et al. // J Biol Chem. – 2020. – Vol. 295, No. 45. – P. 15418–15422.
8. Investigators R.-C., Gordon A.C.,Mouncey PR et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19 // N. Engl. J. Med. 2021. T. 384. pp. 1491-1502.
9. Kotak S., Khatri M., Malik M., Malik M., Hassan W.,Amjad A. Use of Tocilizumab in COVID-19: a systematic review and meta-analysis of current evidence // Cureus. 2020. T. 12, No. 10. P. e10869.
10. Levi M,Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19 // Lancet Haematol. 2020. T. 7, no. 6. pp. e438-e440.

    file

    download